Reviewer's report
Title:Verification of the plasma biomarker, senescence marker protein 30,
previously associated with acute liver failure using mass-spectrometry-based
proteomics
Version: 1Date:29 January 2008
Reviewer: Frank V. V Schiodt
Reviewer's report:
This interesting study from Peking describes the possible role of SMP30 in acute
liver failure. The findings are intriguing but some rewriting and elaboration are
needed.
Major compulsatory revisions: none.
Title: should perhaps be changed to: â##SMP30 in severe acute hepatic disease:
validation of a mass spectrometry proteomics assay.â##
Abstract: Should be rewritten. Background should be more clear, results should
describe how much levels were increased or decreased.
Background: Last paragraph should not indicate results.
Methods: good, but we need to have the 8 groups described in detail here and
not only in figure legends.
Patient protocol: traditionally, ALF is defined as INR > 1.5 and hepatic
encephalopathy (and not jaundice). Did any of the patients have HE? Otherwise I
suggest using the term severe acute hepatic disease.
Results: For the animal model and patients: did you have any data such as INR,
bili, creatinine, ALT? If so, the correlate SMP30 with them (I know that WB is
mainly semiquantitative).
Discussion: generally good. You should leave out the sentence on proteasome
subunit alpha levels since it does not add anything to this paper. â## Are future
human studies justified? I think so.
What next?: Accept after minor essential revisions
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
Reviewer's report
Title:Verification of the plasma biomarker, senescence marker protein 30,
previously associated with acute liver failure using mass-spectrometry-based
proteomics
Version: 1Date:29 January 2008
Reviewer: Frank V. V Schiodt
Reviewer's report:
This interesting study from Peking describes the possible role of SMP30 in acute
liver failure. The findings are intriguing but some rewriting and elaboration are
needed.
Major compulsatory revisions: none.
Title: should perhaps be changed to: â##SMP30 in severe acute hepatic disease:
validation of a mass spectrometry proteomics assay.â##
Abstract: Should be rewritten. Background should be more clear, results should
describe how much levels were increased or decreased.
Background: Last paragraph should not indicate results.
Methods: good, but we need to have the 8 groups described in detail here and
not only in figure legends.
Patient protocol: traditionally, ALF is defined as INR > 1.5 and hepatic
encephalopathy (and not jaundice). Did any of the patients have HE? Otherwise I
suggest using the term severe acute hepatic disease.
Results: For the animal model and patients: did you have any data such as INR,
bili, creatinine, ALT? If so, the correlate SMP30 with them (I know that WB is
mainly semiquantitative).
Discussion: generally good. You should leave out the sentence on proteasome
subunit alpha levels since it does not add anything to this paper. â## Are future
human studies justified? I think so.
What next?: Accept after minor essential revisions
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
Please review this paper.
user
Reviewer's report
Title:Verification of the plasma biomarker, senescence marker protein 30,
previously associated with acute liver failure using mass-spectrometry-based
proteomics
Version: 1Date:29 January 2008
Reviewer: Frank V. V Schiodt
Reviewer's report:
This interesting study from Peking describes the possible role of SMP30 in acute
liver failure. The findings are intriguing but some rewriting and elaboration are
needed.
Major compulsatory revisions: none.
Title: should perhaps be changed to: â##SMP30 in severe acute hepatic disease:
validation of a mass spectrometry proteomics assay.â##
Abstract: Should be rewritten. Background should be more clear, results should
describe how much levels were increased or decreased.
Background: Last paragraph should not indicate results.
Methods: good, but we need to have the 8 groups described in detail here and
not only in figure legends.
Patient protocol: traditionally, ALF is defined as INR > 1.5 and hepatic
encephalopathy (and not jaundice). Did any of the patients have HE? Otherwise I
suggest using the term severe acute hepatic disease.
Results: For the animal model and patients: did you have any data such as INR,
bili, creatinine, ALT? If so, the correlate SMP30 with them (I know that WB is
mainly semiquantitative).
Discussion: generally good. You should leave out the sentence on proteasome
subunit alpha levels since it does not add anything to this paper. â## Are future
human studies justified? I think so.
What next?: Accept after minor essential revisions
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
assistant